论文部分内容阅读
目的探讨米非司酮联合中药治疗子宫肌瘤的临床疗效,为临床保守治疗子宫肌瘤提供新的理论依据。方法 112例子宫肌瘤患者,按照随机数字表法分为观察组和对照组,每组56例。观察组给予米非司酮联合中药治疗,对照组仅给予米非司酮治疗。治疗4个月后,观察并比较两组患者治疗前后以及治疗后组间瘤体体积,比较两组临床治疗有效率,同时测定所有患者治疗前后血红蛋白(Hb)、雌激素(E_2)和孕激素(P)水平。结果 (1)治疗后两组瘤体体积均有缩小,但观察组缩小更明显,差异具有统计学意义(P<0.05);(2)观察组临床疗效(94.64%)高于对照组(71.43%)(P<0.05);(3)治疗后两组患者血清中Hb、E2和P结果优于治疗前(P<0.05),但组间比较差异无统计学意义(P>0.05)。结论米非司酮联合中药治疗子宫肌瘤的效果显著,值得临床推广。
Objective To investigate the clinical efficacy of mifepristone combined with traditional Chinese medicine in the treatment of uterine fibroids and to provide a new theoretical basis for conservative treatment of uterine fibroids. Methods 112 cases of uterine fibroids patients were divided into observation group and control group according to random number table method, 56 cases in each group. The observation group was given mifepristone combined with traditional Chinese medicine, while the control group only received mifepristone. After 4 months of treatment, the volume of tumor in the two groups was observed and compared before and after treatment and after treatment, and the clinical treatment efficiency was compared between the two groups. The levels of hemoglobin (Hb), estrogen (E2) and progesterone (P) level. Results (1) After treatment, the tumor volume of both groups decreased, but the observation group decreased more obviously, the difference was statistically significant (P <0.05); (2) The clinical curative effect in the observation group was 94.64% %) (P <0.05). (3) The serum Hb, E2 and P levels in the two groups after treatment were better than those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05). Conclusion mifepristone combined with Chinese medicine treatment of uterine fibroids significant effect, worthy of clinical promotion.